Postnatal Development of Lung T Lymphocytes in a Porcine Model

May, A. J.; Ramírez-Estudillo, Carmen; Lazo-Vázquez, Gloria; Vega-Lopez, M. A.

doi:10.1007/s00408-014-9622-5

Cited by 4 publications

(4 citation statements)

References 50 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…On the other hand, mucosal immunity is of paramount importance to prevent and control infectious diseases ( 67 ). We compared parenteral (SC) and mucosal (IN) immunization to induce systemic and mucosal immune response and, seeking to avoid tolerance induction and the uncertainty of the mucosal doses administered, a SC/IN protocol was also tested ( 27 , 28 , 45 ). Our results indicated that both IN and SC immunizations stimulate the production of IgA and IgG antibodies, with specific response dynamics and locations ( Figure 5 ).…”

Section: Discussionmentioning

confidence: 99%

“…To test the recombinant protein as an intranasal (IN) immunogen, doses containing 200 μg of the antigen in sterile phosphate buffer without adjuvant were prepared following a previously reported protocol ( 45 ). Briefly, doses containing 200 μg of the antigen in sterile phosphate buffer without adjuvant were prepared.…”

Section: Methodsmentioning

confidence: 99%

“…All animals were immunized four times on days 0, 7, 14, and 42 through either SC or IN routes, depending on the group ( Figure 1A ). At the end of the experiments, animals were humanely euthanized, and bronchoalveolar lavages (BAL) from each animal were obtained as detailed previously ( 45 ).…”

Section: Methodsmentioning

confidence: 99%

See 2 more Smart Citations

Evaluation of the humoral and mucosal immune response of a multiepitope vaccine against COVID-19 in pigs

Mosqueda,

Hernández-Silva,

Vega-López

et al. 2023

Front. Immunol.

View full text Add to dashboard Cite

IntroductionThis study evaluated the immune response to a multiepitope recombinant chimeric protein (CHIVAX) containing B- and T-cell epitopes of the SARS-CoV-2 spike’s receptor binding domain (RBD) in a translational porcine model for pre-clinical studies.MethodsWe generated a multiepitope recombinant protein engineered to include six coding conserved epitopes from the RBD domain of the SARS-CoV-2 S protein. Pigs were divided into groups and immunized with different doses of the protein, with serum samples collected over time to determine antibody responses by indirect ELISA and antibody titration. Peptide recognition was also analyzed by Western blotting. A surrogate neutralization assay with recombinant ACE2 and RBDs was performed. Intranasal doses of the immunogen were also prepared and tested on Vietnamese minipigs.ResultsWhen the immunogen was administered subcutaneously, it induced specific IgG antibodies in pigs, and higher doses correlated with higher antibody levels. Antibodies from immunized pigs recognized individual peptides in the multiepitope vaccine and inhibited RBD-ACE2 binding for five variants of concern (VOC). Comparative antigen delivery methods showed that both, subcutaneous and combined subcutaneous/intranasal approaches, induced specific IgG and IgA antibodies, with the subcutaneous approach having superior neutralizing activity. CHIVAX elicited systemic immunity, evidenced by specific IgG antibodies in the serum, and local mucosal immunity, indicated by IgA antibodies in saliva, nasal, and bronchoalveolar lavage secretions. Importantly, these antibodies demonstrated neutralizing activity against SARS-CoV-2 in vitro.DiscussionThe elicited antibodies recognized individual epitopes on the chimeric protein and demonstrated the capacity to block RBD-ACE2 binding of the ancestral SARS-CoV-2 strain and four VOCs. The findings provide proof of concept for using multiepitope recombinant antigens and a combined immunization protocol to induce a neutralizing immune response against SARS-CoV-2 in the pig translational model for preclinical studies.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Methodsmentioning

confidence: 99%

See 1 more Smart Citation

Evaluation of the humoral and mucosal immune response of a multiepitope vaccine against COVID-19 in pigs

Mosqueda,

Hernández-Silva,

Vega-López

et al. 2023

Front. Immunol.

View full text Add to dashboard Cite

show abstract

“…Animals immunized with recombinant baculoviruses received 5 x 10 8 PFU in the first two doses and 1 x 10 9 PFU in the third and fourth doses, irrespective of the inoculation route. At the end of the experiments, animals were humanely euthanized; bronchoalveolar lavages (BAL) were obtained as detailed in ( 70 ) from pigs immunized with the NG19m antigen.…”

Section: Methodsmentioning

confidence: 99%

Combined Subcutaneous-Intranasal Immunization With Epitope-Based Antigens Elicits Binding and Neutralizing Antibody Responses in Serum and Mucosae Against PRRSV-2 and SARS-CoV-2

et al. 2022

Self Cite

View full text Add to dashboard Cite

New vaccine design approaches, platforms, and immunization strategies might foster antiviral mucosal effector and memory responses to reduce asymptomatic infection and transmission in vaccinated individuals. Here, we investigated a combined parenteral and mucosal immunization scheme to induce local and serum antibody responses, employing the epitope-based antigens 3BT and NG19m. These antigens target the important emerging and re-emerging viruses PRRSV-2 and SARS-CoV-2, respectively. We assessed two versions of the 3BT protein, which contains conserved epitopes from the GP5 envelope protein of PRRSV-2: soluble and expressed by the recombinant baculovirus BacDual-3BT. On the other hand, NG19m, comprising the receptor-binding motif of the S protein of SARS-CoV-2, was evaluated as a soluble recombinant protein only. Vietnamese mini-pigs were immunized employing different inoculation routes: subcutaneous, intranasal, or a combination of both (s.c.-i.n.). Animals produced antigen-binding and neut1ralizing antibodies in serum and mucosal fluids, with varying patterns of concentration and activity, depending on the antigen and the immunization schedule. Soluble 3BT was a potent immunogen to elicit binding and neutralizing antibodies in serum, nasal mucus, and vaginal swabs. The vectored immunogen BacDual-3BT induced binding antibodies in serum and mucosae, but PRRSV-2 neutralizing activity was found in nasal mucus exclusively when administered intranasally. NG19m promoted serum and mucosal binding antibodies, which showed differing neutralizing activity. Only serum samples from subcutaneously immunized animals inhibited RBD-ACE2 interaction, while mini-pigs inoculated intranasally or via the combined s.c.-i.n. scheme produced subtle neutralizing humoral responses in the upper and lower respiratory mucosae. Our results show that intranasal immunization, alone or combined with subcutaneous delivery of epitope-based antigens, generates local and systemic binding and neutralizing antibodies. Further investigation is needed to evaluate the capability of the induced responses to prevent infection and reduce transmission.

show abstract

Mucosal and systemic immune responses to Aujeszky’s disease virus (ADV) in early vaccinated piglets

Salinas-Zacarias

Guzman-Bautista

Ramírez-Estudillo

et al. 2020

Comparative Immunology, Microbiology and Infectious Diseases

View full text Add to dashboard Cite

Postnatal Development of Lung T Lymphocytes in a Porcine Model

Cited by 4 publications

References 50 publications

Evaluation of the humoral and mucosal immune response of a multiepitope vaccine against COVID-19 in pigs

Evaluation of the humoral and mucosal immune response of a multiepitope vaccine against COVID-19 in pigs

Combined Subcutaneous-Intranasal Immunization With Epitope-Based Antigens Elicits Binding and Neutralizing Antibody Responses in Serum and Mucosae Against PRRSV-2 and SARS-CoV-2

Mucosal and systemic immune responses to Aujeszky’s disease virus (ADV) in early vaccinated piglets

Contact Info

Product

Resources

About